The drug metformin has been shown to protect against liver cancer by inhibiting FASN in DEN-induced and AKT-overexpression models of HCC (Bhalla et al., 2012; Zhang et al., 2019). The gene discussed is AKT1; the disease is hepatocellular carcinoma.